Coadministration of erlotinib and curcumin augmentatively reduces cell viability in lung cancer cells

Phytotherapy Research

Volumn 28, Issue 5, 2014, Pages 728-735

  Yamauchi, Yoshikane ^a   Izumi, Yotaro ^a   Yamamoto, Jun ^a   Nomori, Hiroaki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

curcumin; erlotinib; ikappaB; NFkappaB

Indexed keywords

CASPASE 3; CURCUMIN; ERLOTINIB; I KAPPA B; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; LUNG CANCER; MALE; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; UPREGULATION;

MUS;

CURCUMIN; ERLOTINIB; IKAPPAB; NFKAPPAB;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; HUMANS; I-KAPPA B PROTEINS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; QUINAZOLINES; RNA INTERFERENCE;

EID: 84899489037     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5056     Document Type: Article

References (29)

1. Aggarwal BB, Kumar A, Bharti AC,. 2003. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363-98.
2. Andjelkovic T, Pesic M, Bankovic J, Tanic N, Markovic ID, Ruzdijic S,. 2008. Synergistic effects of the purine analog sulfinosine and curcumin on the multidrug resistant human non-small cell lung carcinoma cell line (NCI-H460/R). Cancer Biol Ther 7: 1024-32.
3. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y,. 2007. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 72: 29-39.
4. Bean J, Brennan C, Shih J-Y, et al,. 2007. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20,932-7.
5. Bivona TG, Hieronymus H, Parker J, et al,. 2011. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 471: 523-6.
6. Chanvorachote P, Pongrakhananon V, Wannachaiyasit S, Luanpitpong S, Rojanasakul Y, Nimmannit U,. 2009. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation. Cancer Investig 27: 624-35.
7. Engelman JA, Mukohara T, Zejnullahu K, et al,. 2006. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Investig 116: 2695-706.
8. Fukuoka M, Yano S, Giaccone G, et al,. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol: Off J Am Soc Clin Oncol 21: 2237-46.
9. Goel A, Aggarwal BB,. 2010a. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62: 919-30.
10. Goel A, Aggarwal BB,. 2010b. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62: 919-30.
11. Herbst RS, Fukuoka M, Baselga J,. 2004. Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 4: 956-65.
12. Inoue A, Suzuki T, Fukuhara T, et al,. 2006. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol: Off J Am Soc Clin Oncol 24: 3340-6.
13. Ishikawa Y, Kubota T, Otani Y, et al,. 1999. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Rese: An Off J Am Assoc Cancer Res 5: 883-9.
14. Ju L, Zhou C, Li W, Yan L,. 2010. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer. J Cell Biochem 111: 1565-74.
15. Kris MG, Natale RB, Herbst RS, et al,. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA: J Am Med Assoc 290: 2149-58.
16. Lin C, Lin J-kun,. 2008. Curcumin: a potential cancer chemopreventive agent through suppressing NF-kappaB signaling. J Cancer Molecules 4: 11-16.
17. Lin H-P, Kuo L-K, Chuu C-P,. 2011a. Combined Treatment of Curcumin and Small Molecule Inhibitors Suppresses Proliferation of A549 and H1299 Human Non-Small-Cell Lung Cancer Cells. Phytother Res: PTR 26: 122-6.
18. Lin H-P, Kuo L-K, Chuu C-P,. 2011b. Combined Treatment of Curcumin and Small Molecule Inhibitors Suppresses Proliferation of A549 and H1299 Human Non-Small-Cell Lung Cancer Cells. Phytother Res: PTR 26: 122-6.
19. Okabe T, Okamoto I, Tamura K, et al,. 2007. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res 67: 2046-53.
20. Ramachandran C, Rodriguez S, Ramachandran R, et al,. 2005. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res 25: 3293-3302.
21. Reuter S, Eifes S, Dicato M, Aggarwal BB, Diederich M,. 2008. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 76: 1340-51.
22. Sen S, Sharma H, Singh N,. 2005. Curcumin enhances Vinorelbine mediated apoptosis in NSCLC cells by the mitochondrial pathway. Biochem Biophys Res Commun 331: 1245-52.
23. Sharma SV, Bell DW, Settleman J, Haber DA,. 2007. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-81.
24. Simonetti S, Molina MA, Queralt C, et al,. 2010. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J transl Med 8: 135.
25. Su C-C, Yang J-S, Lu C-C, et al,. 2010. Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. Phytother Res: PTR 24: 189-92.
26. Surh Y-J,. 2003. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-80.
27. Sutani A, Nagai Y, Udagawa K, et al,. 2006. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 95: 1483-9.
28. Thomson S, Buck E, Petti F, et al,. 2005a. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65: 9455-62.
29. Thomson S, Buck E, Petti F, et al,. 2005b. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65: 9455-62.